

## **Acquisition of Innogenetics nv – Additional disclosures as of 30/09/2008**

The net assets and goodwill<sup>(1)</sup> acquired in the transaction are as follows:

EUR million	Carrying amount before acquisition	Fair value adjustments	Total
Intangible assets	19	0	19
Tangible assets	12	0	12
Other investments	3	0	3
Deferred tax assets	0	0	0
Financial receivables and other non-current assets	2	0	2
<b>Non-current assets</b>	<b>36</b>	<b>0</b>	<b>36</b>
Current assets other than cash and cash equivalents	21	0	21
Cash and cash equivalents	8	0	8
<b>Current assets</b>	<b>29</b>	<b>0</b>	<b>29</b>
Long-term provisions	0	0	0
Deferred tax liabilities	0	0	0
Long-term financial debt	11	0	11
<b>Non-current liabilities</b>	<b>11</b>	<b>0</b>	<b>11</b>
<b>Current liabilities</b>	<b>58</b>	<b>0</b>	<b>58</b>
<b>Net assets</b>	<b>-4</b>	<b>0</b>	<b>-4</b>
<b>Group share (84.3%)</b>			<b>-4</b>
<b>Minority interests</b>			<b>-1</b>
Goodwill			193
<b>Price paid</b>			<b>189 (2)</b>

<sup>(1)</sup> The opening balance sheet of Innogenetics nv is provisional because of time constraints. Part of the goodwill will be allocated to intangible assets in the coming months.

<sup>(2)</sup> Of which EUR 157 million paid in the 3rd quarter 2008 (including EUR 2 million of acquisition costs) and EUR 32 million for shares previously owned.

If the Solvay Group had acquired and consolidated Innogenetics nv on July 1, 2008, the impact over the third quarter 2008 would have amounted to EUR 8 million on revenue and - EUR 13 million on net income.